Inclusion Criteria: 

• Skeletally mature Male or Female age at or above the age of consent 18-80 (inclusive) at time of signing informed consent and skeletally mature (as determined by physician’s assessment of AP lumbar Xray utilizing the Risser Classification method of the iliac crest growth plates) (See Appendix 2 for a definitive reference on skeletal age).
• Subject is planning to undergo a unilateral, single-level, single interbody cage TLIF procedure (from L2-S1 with posterior supplemental fixation) with a primary diagnosis of symptomatic lumbar disc degeneration including back and/or radicular pain with or without foraminal or recess stenosis confirmed by patient history, physical examinations, and radiographic imaging (x-ray, 
• CT, MRI) with no more than Grade 2 Spondylolisthesis with one or more of the following factors:
  • Instability as defined by ≥ 3mm translation or ≥5° angulation;
  • Osteophyte formation of facet joints or vertebral endplates;
  • Decreased disc height, on average by > 2mm, but dependent upon the spinal level;
  • Scarring/thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule;
  • Herniated nucleus pulposus; facet joint degeneration/changes; and/or.
• A Body Mass Index of ≤ 40 at screening
• Preoperative ODI score ≥ 40 at pre-op/baseline;
• Preoperative back and/or leg pain score of ≥ 4 (out of 10);
• Failed ≥6 months non-operative/conservative treatment (e.g., physical therapy, bracing, traction, medication, TENS, and/or spinal injections;
• Is willing and able to be present for routine follow up visits, comply with postoperative management program, and is able to understand and sign the informed consent form.

Exclusion Criteria: 

• Prior spinal fusion surgical procedure at the involved or adjacent spinal levels, or non-fusion stabilizing surgeries, e.g., interlaminar devices, dynamic stabilization, or disc replacements.  (Prior non-fusion surgery at the target levels, including discectomy and/or single-level foraminotomy or laminectomy, is allowed.)
• Planned use of an internal or external bone growth stimulator;
• Osteoporosis to a degree that spinal instrumentation is contraindicated or a history of a traumatic vertebral fracture. All patients complete SCORE/MORE to assess the need for DEXA scan. If DEXA is required, patients with a spinal T score ≤ - 2.5 will be excluded A prior DEXA can be used if performed within 9 months pre-op;
• Overt or active bacterial infection, either local or systemic;
• The subject uses, or has used within 30 days of surgery, tobacco or nicotine or is prescribed steroids such as cortisone; (subjects will undergo a nicotine test during screening procedures utilizing a standard commercial cotinine urine dip test; Example: Easy@Home Nicotine Cotinine Urine Panel Dip test Strips Kit – Sensitive (healthcare-manager.com)
• Comorbidities precluding subject from being a surgical candidate;
• Positive test results for active human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the screening visit.
• Systemic disease including Lupus disease, Reiter’s disease, Rheumatoid disease, or autoimmune disease that requires immunosuppressive therapy, including biologics, for systemic inflammation.
• Presence or history of malignancy (excludes surgically resected skin squamous cell or basal cell carcinoma), radiotherapy, or chemotherapy for any malignancy within the last 5 years. History of malignancy may include multiple exostoses syndrome ((also known as multiple osteochondromas syndrome), an inherited condition associated with bumps of cartilage on the bones, has been associated with an increased risk of chondrosarcoma); individuals with hereditary cancer syndromes are excluded. Examples of hereditary cancer syndromes are hereditary breast and ovarian cancer syndrome, Li-Fraumeni syndrome, Cowden syndrome, and Lynch syndrome. Also 
• called family cancer syndrome and inherited cancer syndrome individuals who have undergone any transplant surgery and are on immunosuppressant therapy.
• Has history of any endocrine or metabolic disorder known to affect osteogenesis (e.g.: Paget's disease, renal osteodystrophy, Ehler-Danlos syndrome, or osteogenesis imperfecta);
• Insulin dependent diabetes;
• History of exposure to any recombinant proteins or peptides used for bone formation (i.e., Infuse Bone Graft, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft);
• Hypersensitivity or allergy to any components of the study treatments including, but not limited to, bone morphogenetic proteins (BMPs); tricalcium phosphate (TCP); PLGA polymer; and/or instrumentation materials (titanium, titanium alloy, PEEK).
• History of any allergy resulting in anaphylaxis;
• Is a prisoner;
• Is mentally incompetent. If questionable, obtain psychiatric consult;
• History of substance abuse (substance abuse defined by DSM-5 (The Diagnostic and Statistical Manual of Mental Disorders) code. Criteria for substance abuse defined in Appendix 3.
• Involved in litigation for spine injury or worker’s compensation case;
• Treatment with an investigational therapy (drug, device, and/or biologic) within 120 days (or 5 half-lives , whichever is greater) prior to implantation surgery, or such treatment is planned during the 24-month period following implantation of the study treatment; prior or planned use of rhBMP-2.
• Pregnant at Screening and Day 1 pre-surgery (or interested in becoming pregnant in the next 24 months or nursing.  Double contraception is recommended by all childbearing females and males with or without a prior vasectomy. Tests will be administered at the surgical center prior to surgery.
• Any condition that would interfere with the subject's ability to comply with study instructions or prohibit MRI/CT/Radiographic assessments that might confound the interpretation of the study or put the subject at risk.
• Patients currently taking any drug known to interfere with bone/soft tissue healing. See “Medication Protocol” section of the Investigator’s Brochure. See note below containing the Medication Protocol language.
• Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/08/2024. Questions regarding updates should be directed to the study team contact.